Enovis Corporation
Financials
Valuation Metrics
Enovis Corporation's Market Cap is $1.04B. At end of 2025 it was $1.51B. Ranked #2460 of 3,121 in US market (top 79%), #1452 of 1,658 on NYSE (top 88%), #155 of 205 in Health Care Equipment & Services (top 76%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.04B | US#2,460/3,121 Sec#155/205 |
| Revenue | $2.30B | US#1,357/3,121 Sec#85/205 |
| Net Income | $-1.10B | US—/3,121 Sec—/205 |
| Total Assets | $3.77B | US#1,642/3,121 Sec#76/205 |
| Net Assets | $1.48B | US#1,488/3,121 Sec#77/205 |
| Employees | 7,802 | US#993/3,121 Sec#76/205 |
| Value | ||
| P/B | 0.70x | US#152/3,121 Sec#9/205 |
| P/S | 0.45x | US#269/3,121 Sec#24/205 |
| FCF Yield | 6.13% | US#1,161/3,121 Sec#49/205 |
| Profitability | ||
| ROE | -74.59% | US#2,764/3,121 Sec#177/205 |
| ROA | -29.25% | US#2,876/3,121 Sec#186/205 |
| Op. Margin | 4.14% | US#2,070/3,121 Sec#110/205 |
| Revenue Growth | 4.89% | US#1,823/3,121 Sec#134/205 |
| Financial Health | ||
| Debt Ratio | 154.83% | US#1,536/3,121 Sec#136/205 |
| Total Debt | $1.37B | US#1,383/3,121 Sec#72/205 |
| FCF | $64M | US#1,898/3,121 Sec#114/205 |
| Cash | $13M | US#2,945/3,121 Sec#197/205 |
| Current Ratio | 1.98x | US#1,260/3,121 Sec#109/205 |
| Performance | ||
| 1Y Return | -45.61% | US#2,853/3,121 Sec#186/205 |
| 1M Return | -31.92% | US#3,078/3,121 Sec#203/205 |
| From 52W High | -47.37% | US#2,666/3,121 Sec#174/205 |
| 1Y MDD | -45.85% | US#2,281/3,121 Sec#137/205 |
| Trading | ||
| Volume | 1,200,080 shares | US#846/3,121 Sec#48/205 |
| Trading Value | $21M | US#1,510/3,121 Sec#109/205 |
| Per Share | ||
| EPS | $-19.14 | US—/3,121 Sec—/205 |
| BPS | $25.66 | US#1,023/3,121 Sec#62/205 |
Company Info
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.